首页 / 院系成果 / 成果详情页

Co-optimization of algorithm and sensor array for precise diagnosis of HER2-positive breast cancer and trastuzumab response prediction 期刊论文

编号：

3DE24B1D0B4377BDA371B8E514B4FCD0
作者：

Zeng, Tianyu#^[1]Li, Zeying^[1];Sun, Yanting^[1];Liu, Yincheng^[2];Xu, Jialin^[1];Huang, Xiang(黄香)^[1]Liang, Yan^[1];Shi, Hai^[3];Wu, Shuai*^[4]Li, Genxi*^[5,6]Yin, Yongmei(殷咏梅)*^[1]
语种：

英文
期刊：

ADVANCED COMPOSITES AND HYBRID MATERIALS ISSN：2522-0128 2026 年 9 卷 2 期 ; FEB 9
收录：
关键词：

Sensor array Hydrogen-bonded organic frameworks HER2-positive breast cancer Exosome Machine learning
摘要：

Accurate and rapid diagnosis of human epidermal growth factor receptor-2 (HER2)-positive breast cancer, coupled with prediction of trastuzumab therapeutic efficacy, is critical for clinical decision-making to the patients with breast cancer. However, there is still no standard to be clinically used without suffering from inherent limitations. In this work, we propose a machine learning-assisted multifunctional biosensing platform utilizing enzyme-embedded hydrogen-bonded organic frameworks (HOFs). In this design, diverse HOFs@enzyme composites with distinct assembly configurations serve as sensitive array elements to interact with breast cancer-derived exosomes. Moreover, these interactions can modulate HOF-enzyme activity, generating diagnostic signal patterns that form unique exosomal molecular "fingerprint" profiles. Simultaneously, coordination with machine learning enables processing of complex sensor array-based data to amplify subtle differences of exosome between different subtypes of breast cancer, thereby enhancing the discriminatory capacity of this platform. By establishing reference fingerprints using exosomes from 96 training-set patients and validating classification accuracy against immunohistochemical in 76 test-set patients, the platform achieved 100% concordance in identifying the HER2-positive subtype, demonstrating exceptional discriminative capacity. Remarkably, the platform can also predict trastuzumab treatment response with 87.5% accuracy through clinical outcome correlation. So, by enabling precise exosome characterization from peripheral blood, this non-invasive liquid biopsy technology offers a transformative approach for precision oncology in HER2-positive breast cancer, overcoming critical limitations of current diagnostic paradigms.
推荐引用方式
GB/T 7714：

Zeng Tianyu,Li Zeying,Sun Yanting, et al. Co-optimization of algorithm and sensor array for precise diagnosis of HER2-positive breast cancer and trastuzumab response prediction [J].ADVANCED COMPOSITES AND HYBRID MATERIALS,2026,9(2).
APA：

Zeng Tianyu,Li Zeying,Sun Yanting,Liu Yincheng,&Yin Yongmei.(2026).Co-optimization of algorithm and sensor array for precise diagnosis of HER2-positive breast cancer and trastuzumab response prediction .ADVANCED COMPOSITES AND HYBRID MATERIALS,9(2).
MLA：

Zeng Tianyu, et al. "Co-optimization of algorithm and sensor array for precise diagnosis of HER2-positive breast cancer and trastuzumab response prediction" .ADVANCED COMPOSITES AND HYBRID MATERIALS 9,2(2026).
入库时间：

3/16/2026 10:05:43 PM
更新时间：

3/16/2026 10:05:43 PM

浏览次数：6  下载次数：0

分享到：

浏览次数：6

下载次数：0

打印次数：0